CO2019002556A2 - Composición farmacéutica - Google Patents
Composición farmacéuticaInfo
- Publication number
- CO2019002556A2 CO2019002556A2 CONC2019/0002556A CO2019002556A CO2019002556A2 CO 2019002556 A2 CO2019002556 A2 CO 2019002556A2 CO 2019002556 A CO2019002556 A CO 2019002556A CO 2019002556 A2 CO2019002556 A2 CO 2019002556A2
- Authority
- CO
- Colombia
- Prior art keywords
- pharmaceutical composition
- component
- glycopyrrolate
- hfa
- difluoroethane
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/124—Aerosols; Foams characterised by the propellant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describe una composición farmacéutica. La composición comprende: (i) un componente de fármaco que comprende al menos una sal aceptable desde el punto de vista farmacéutico de glicopirrolato; y (ii) un componente propulsor que comprende 1,1-difluoroetano (HFA-152a).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1615917.0A GB2558191A (en) | 2016-09-19 | 2016-09-19 | Pharmaceutical composition |
GBGB1620519.7A GB201620519D0 (en) | 2016-12-02 | 2016-12-02 | Pharmaceutical composition |
PCT/GB2017/052761 WO2018051130A1 (en) | 2016-09-19 | 2017-09-18 | Pharmaceutical composition |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2019002556A2 true CO2019002556A2 (es) | 2020-02-18 |
Family
ID=59997386
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2019/0002556A CO2019002556A2 (es) | 2016-09-19 | 2019-03-19 | Composición farmacéutica |
Country Status (18)
Country | Link |
---|---|
US (9) | US10888546B2 (es) |
EP (4) | EP3610871B1 (es) |
JP (3) | JP6781829B2 (es) |
KR (2) | KR102277635B1 (es) |
CN (4) | CN109789126B (es) |
AU (3) | AU2017328907B2 (es) |
BR (1) | BR112019005133A2 (es) |
CA (1) | CA3037092C (es) |
CO (1) | CO2019002556A2 (es) |
ES (4) | ES2957459T3 (es) |
GE (1) | GEP20217239B (es) |
IL (1) | IL265360B2 (es) |
MX (3) | MX2019003098A (es) |
MY (1) | MY202069A (es) |
PE (1) | PE20191043A1 (es) |
PH (1) | PH12019500579A1 (es) |
UA (1) | UA123919C2 (es) |
WO (1) | WO2018051130A1 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9421199B2 (en) | 2014-06-24 | 2016-08-23 | Sydnexis, Inc. | Ophthalmic composition |
US11382909B2 (en) | 2014-09-05 | 2022-07-12 | Sydnexis, Inc. | Ophthalmic composition |
EP3610871B1 (en) * | 2016-09-19 | 2023-11-08 | Mexichem Fluor S.A. de C.V. | Pharmaceutical composition comprising glycopyrrolate |
ES2877575T3 (es) | 2016-09-19 | 2021-11-17 | Mexichem Fluor Sa De Cv | Composición farmacéutica que comprende salmeterol |
GEP20217240B (en) * | 2016-09-19 | 2021-03-25 | Mexichem Fluor Sa De Cv | Pharmaceutical composition |
JP6781831B2 (ja) * | 2016-09-19 | 2020-11-04 | メキシケム フロー エセ・ア・デ・セ・ヴェ | 医薬組成物 |
KR102041239B1 (ko) * | 2017-02-22 | 2019-11-06 | 도레이첨단소재 주식회사 | 이형필름 |
WO2019104191A1 (en) * | 2017-11-21 | 2019-05-31 | Sydnexis, Inc. | Ophthalmic composition and delivery device thereof |
GB2573297A (en) * | 2018-04-30 | 2019-11-06 | Mexichem Fluor Sa De Cv | Pharmaceutical composition |
JP2021527057A (ja) * | 2018-06-07 | 2021-10-11 | キンデーバ ドラッグ デリバリー リミティド パートナーシップ | フルチカゾン及びビランテロール製剤並びに吸入器 |
CN112137957B (zh) * | 2019-06-26 | 2022-07-29 | 长风药业股份有限公司 | 一种药用吸入气雾剂及其制备方法 |
GB2586477A (en) * | 2019-08-20 | 2021-02-24 | Mexichem Fluor Sa De Cv | Composition and method |
GB2593283B (en) | 2020-01-28 | 2023-09-13 | Chiesi Farm Spa | Pressurised metered dose inhalers comprising a buffered pharmaceutical formulation |
GB2593970A (en) | 2020-02-20 | 2021-10-13 | Chiesi Farm Spa | Pressurised metered dose inhalers comprising a buffered pharmaceutical formulation |
CN111624292A (zh) * | 2020-07-10 | 2020-09-04 | 武汉伯瑞恒医药科技有限公司 | 一种测定血清中茚达特罗格隆溴铵浓度的方法 |
CN112051346A (zh) * | 2020-09-24 | 2020-12-08 | 珠海瑞思普利生物制药有限公司 | 一种同时测定茚达特罗和格隆溴铵含量的hplc方法 |
CA3230792A1 (en) * | 2021-09-08 | 2023-03-16 | Kindeva Drug Delivery L.P. | Metered dose inhalers and solution compositions |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8828477D0 (en) | 1988-12-06 | 1989-01-05 | Riker Laboratories Inc | Medical aerosol formulations |
US5439670A (en) | 1989-11-28 | 1995-08-08 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
IE67185B1 (en) | 1990-02-02 | 1996-03-06 | Fisons Plc | Propellant compositions |
DE4003272A1 (de) | 1990-02-03 | 1991-08-08 | Boehringer Ingelheim Kg | Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen |
GB9024366D0 (en) | 1990-11-09 | 1991-01-02 | Glaxo Group Ltd | Medicaments |
US6123924A (en) | 1991-09-25 | 2000-09-26 | Fisons Plc | Pressurized aerosol inhalation compositions |
FR2718437B1 (fr) * | 1994-04-11 | 1996-06-28 | Solvay | Procédé de séparation du 1,1-difluoroéthane de ses mélanges avec le fluorure d'hydrogène. |
MX9704550A (es) | 1994-12-22 | 1997-10-31 | Astra Ab | Formulaciones de medicamentos en aerosol. |
DE69814428T2 (de) | 1997-09-29 | 2004-05-13 | Nektar Therapeutics, San Carlos | In verneblern verwendbare, stabilisierte zubereitungen |
US6103266A (en) | 1998-04-22 | 2000-08-15 | Tapolsky; Gilles H. | Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues |
US6451285B2 (en) | 1998-06-19 | 2002-09-17 | Baker Norton Pharmaceuticals, Inc. | Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant |
ATE283033T1 (de) * | 1998-07-24 | 2004-12-15 | Jago Res Ag | Medizinische aerosolformulierungen |
EP1102579B1 (de) | 1998-08-04 | 2003-03-19 | Jago Research Ag | Medizinische aerosolformulierungen |
US6004537A (en) | 1998-12-18 | 1999-12-21 | Baker Norton Pharmaceuticals, Inc. | Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol |
US6432415B1 (en) | 1999-12-17 | 2002-08-13 | Axrix Laboratories, Inc. | Pharmaceutical gel and aerosol formulations and methods to administer the same to skin and mucosal surfaces |
ES2238334T3 (es) | 1999-12-24 | 2005-09-01 | Glaxo Group Limited | Formulacion farmaceutica en aerosol de salmeterol y propionato de fluticasona. |
US20060257324A1 (en) | 2000-05-22 | 2006-11-16 | Chiesi Farmaceutici S.P.A. | Pharmaceutical solution formulations for pressurised metered dose inhalers |
US6908928B2 (en) | 2000-10-12 | 2005-06-21 | Bi Pharma Kg. | Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions |
CN1144582C (zh) | 2000-11-28 | 2004-04-07 | 中国药科大学 | 治疗呼吸系统疾病的无氟里昂药用气雾剂 |
CN1216600C (zh) | 2002-04-24 | 2005-08-31 | 信谊药厂 | 盐酸左旋沙丁胺醇气雾剂及制备工艺 |
US7244742B2 (en) * | 2002-08-17 | 2007-07-17 | Boehringer Ingelheim Pharma Gmbh & Co Kg | Pharmaceutical compositions for inhalation containing an anticholinergic, corticosteroid and betamimetic |
EP2319584A1 (en) | 2002-08-29 | 2011-05-11 | Cipla Ltd. | Pharmaceutical products and compositions comprising salmeterol, ciclesonide and tiotropium |
KR20050085650A (ko) | 2002-12-16 | 2005-08-29 | 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 | 타이오트로피움 함유 hfc 용액 제형 |
GB0323685D0 (en) | 2003-10-09 | 2003-11-12 | Jagotec Ag | Improvements in or relating to organic compounds |
GB0323684D0 (en) | 2003-10-09 | 2003-11-12 | Jagotec Ag | Improvements in or relating to organic compounds |
US20060018840A1 (en) | 2004-06-28 | 2006-01-26 | Nektar Therapeutics | Aerosolizable formulation comprising nicotine |
ES2259915B1 (es) | 2005-03-15 | 2007-12-16 | Laboratorio Aldo-Union, S.A. | Nueva formulacion estable de aerosoles en suspension y procedimiento de obtencion. |
WO2007020204A2 (en) | 2005-08-12 | 2007-02-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Hfc solution formulations for inhalation containing salbutamol hydrochloride or salbutamol citrate |
DE102006017320A1 (de) | 2006-04-11 | 2007-10-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Aerosolsuspensionsformulierungen mit TG 227 ea oder TG 134 a als Treibmittel |
PL3111926T3 (pl) | 2009-05-29 | 2020-06-29 | Pearl Therapeutics, Inc. | Kompozycje, sposoby i układy do dostarczania dwóch lub większej liczby środków czynnych do układu oddechowego |
US8815258B2 (en) * | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
WO2011076842A2 (en) * | 2009-12-23 | 2011-06-30 | Chiesi Farmaceutici S.P.A. | Aerosol formulation for copd |
EP2515855B3 (en) * | 2009-12-23 | 2023-05-03 | Chiesi Farmaceutici S.p.A. | Combination therapy for COPD |
EP2749284A3 (en) * | 2011-02-17 | 2014-08-20 | Cipla Limited | Combination of glycopyrronium and carmoterol |
GB201108039D0 (en) * | 2011-05-13 | 2011-06-29 | Mexichem Amanco Holding Sa | Compositions |
GB201117621D0 (en) * | 2011-10-12 | 2011-11-23 | Mexichem Amanco Holding Sa | Compositions |
GB201117619D0 (en) * | 2011-10-12 | 2011-11-23 | Mexichem Amanco Holding Sa | Compositions |
MX2015003731A (es) | 2012-10-23 | 2015-06-15 | Cipla Ltd | Composicion farmaceutica. |
SG11201605311UA (en) | 2013-12-30 | 2016-07-28 | Chiesi Farma Spa | Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination |
WO2017093758A1 (en) | 2015-12-04 | 2017-06-08 | Mexichem Fluor S.A. De C.V. | Pharmaceutical composition |
EP3610871B1 (en) * | 2016-09-19 | 2023-11-08 | Mexichem Fluor S.A. de C.V. | Pharmaceutical composition comprising glycopyrrolate |
ES2877575T3 (es) * | 2016-09-19 | 2021-11-17 | Mexichem Fluor Sa De Cv | Composición farmacéutica que comprende salmeterol |
-
2017
- 2017-09-18 EP EP19199783.2A patent/EP3610871B1/en active Active
- 2017-09-18 ES ES21183659T patent/ES2957459T3/es active Active
- 2017-09-18 JP JP2019515227A patent/JP6781829B2/ja active Active
- 2017-09-18 UA UAA201902770A patent/UA123919C2/uk unknown
- 2017-09-18 EP EP21183659.8A patent/EP3915555B1/en active Active
- 2017-09-18 CN CN201780057068.5A patent/CN109789126B/zh active Active
- 2017-09-18 EP EP17777635.8A patent/EP3515432B1/en active Active
- 2017-09-18 BR BR112019005133A patent/BR112019005133A2/pt unknown
- 2017-09-18 AU AU2017328907A patent/AU2017328907B2/en active Active
- 2017-09-18 US US16/334,158 patent/US10888546B2/en active Active
- 2017-09-18 ES ES19199780T patent/ES2968212T3/es active Active
- 2017-09-18 MX MX2019003098A patent/MX2019003098A/es unknown
- 2017-09-18 CN CN202210090190.5A patent/CN114515284A/zh active Pending
- 2017-09-18 GE GEAP201715035A patent/GEP20217239B/en unknown
- 2017-09-18 EP EP19199780.8A patent/EP3607936B1/en active Active
- 2017-09-18 CA CA3037092A patent/CA3037092C/en active Active
- 2017-09-18 CN CN202210401223.3A patent/CN114712338A/zh active Pending
- 2017-09-18 ES ES17777635T patent/ES2892673T3/es active Active
- 2017-09-18 WO PCT/GB2017/052761 patent/WO2018051130A1/en active Application Filing
- 2017-09-18 MY MYPI2019001316A patent/MY202069A/en unknown
- 2017-09-18 ES ES19199783T patent/ES2968453T3/es active Active
- 2017-09-18 KR KR1020197010385A patent/KR102277635B1/ko active Application Filing
- 2017-09-18 CN CN202210090188.8A patent/CN114272238A/zh active Pending
- 2017-09-18 PE PE2019000674A patent/PE20191043A1/es unknown
- 2017-09-18 KR KR1020217021521A patent/KR20210089273A/ko not_active Application Discontinuation
- 2017-09-18 MX MX2021009476A patent/MX2021009476A/es unknown
-
2019
- 2019-03-13 IL IL265360A patent/IL265360B2/en unknown
- 2019-03-15 MX MX2021009475A patent/MX2021009475A/es unknown
- 2019-03-18 PH PH12019500579A patent/PH12019500579A1/en unknown
- 2019-03-19 CO CONC2019/0002556A patent/CO2019002556A2/es unknown
- 2019-09-25 US US16/582,973 patent/US11103480B2/en active Active
- 2019-09-25 US US16/582,993 patent/US11179366B2/en active Active
-
2020
- 2020-03-10 JP JP2020040655A patent/JP7041703B2/ja active Active
- 2020-04-17 AU AU2020202626A patent/AU2020202626B2/en active Active
-
2021
- 2021-06-29 US US17/361,772 patent/US11642330B2/en active Active
- 2021-06-29 US US17/361,851 patent/US11826349B2/en active Active
- 2021-06-29 US US17/361,819 patent/US11826348B2/en active Active
- 2021-07-14 AU AU2021205045A patent/AU2021205045C1/en active Active
- 2021-09-07 US US17/467,778 patent/US11690823B2/en active Active
-
2022
- 2022-02-16 JP JP2022022292A patent/JP7228726B2/ja active Active
-
2023
- 2023-10-18 US US18/489,150 patent/US20240050405A1/en active Pending
- 2023-10-18 US US18/489,133 patent/US20240050404A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2019002556A2 (es) | Composición farmacéutica | |
EP4331677A3 (en) | Methods of treating feline coronavirus infections | |
DOP2016000298A (es) | Pirazolopiridinas y pirazolopirimidinas | |
CR20170411A (es) | Composiciones farmacéuticas que comprenden n-(3,5-dimetoxifenil)-n-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il-quin oxalin-6-il]etano-1,2-diamina | |
CO2019002555A2 (es) | Composición farmacéutica | |
AR107864A1 (es) | ÁCIDO 7a,11b-DIHIDROXI-6a-ETIL-5b-COLAN-24-OICO Y COMPOSICIONES FARMACÉUTICAS | |
GEP20237470B (en) | Magl inhibitors | |
PA8809601A1 (es) | Combinación anti-retroviral | |
MX2019003097A (es) | Composicion farmaceutica. | |
CO2018001700A2 (es) | Derivados de n-[1h-bencimidazol-2-il] metil-pirazin-2-il-carboxamida, composiciones y procedimientos de preparación de los mismos | |
CL2017001483A1 (es) | Formulación de relación fija de insulina glargina/lixisenatida | |
MX2020003732A (es) | Derivado de anillo fusionado como inhibidor del receptor a2a. | |
CL2018001407A1 (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer | |
AR094707A1 (es) | Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2 | |
AR104257A1 (es) | Tableta de ribociclib | |
AR115913A1 (es) | Formas de dosificación oral biodisponibles, uso, métodos | |
CO2017008115A2 (es) | Ácido (2s,4r)-5-(5'-cloro-2'-fluorobifenil-4-il)-4-(etoxioxalilamino)-2-hidroximetil-2-metilpentanoico | |
UY38892A (es) | Moduladores de sting (estimulador de genes de interferón) | |
CL2020002199A1 (es) | Compuesto de anillo de metillactama y uso farmacéutico del mismo. | |
MX2021010022A (es) | Composicion farmaceutica. | |
CL2018001408A1 (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer | |
MX2020011504A (es) | Composicion farmaceutica que comprende salbutamol. | |
EA201991373A1 (ru) | МОДУЛЯТОРЫ ROR ГАММА (RORγ) | |
AR104241A1 (es) | Derivados de tetrahidrofuro tiazina como inhibidores de bace1 selectivos | |
BR112022005728A2 (pt) | Compostos de tiazol carboxamida e seu uso para o tratamento de infecções micobacterianas |